# Sunstone Life Science Ventures

> Sunstone Life Science Ventures is a VC fund backing Biotechnology. See 61 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Copenhagen, Denmark
- Total investments: 61
- Last investment: Dec 2025
- Lead investor: 16%
- Fund size: $94M
- Last fund: Feb 2019
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/company/sunstone-life-science-ventures
- Website: https://sunstone.eu/

Sunstone Life Science Ventures is a European, early-stage VC investing in novel pharmaceutical ingredients for human therapeutic use

## Contacts

5 contacts available for Sunstone Life Science Ventures. Shizune tracks 8 team members at Sunstone Life Science Ventures. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/sunstone-capital-life-science?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $5.5M–$44M |
| Series B | $9.6M–$52M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 23 | 38% |
| Health Care | 22 | 36% |
| Medical | 14 | 23% |
| Therapeutics | 10 | 16% |
| Pharmaceutical | 9 | 15% |

26 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 12 | 20% |
| Funding Round | 12 | 20% |
| Series B | 11 | 18% |
| Series C | 8 | 13% |
| Post-IPO Equity | 3 | 5% |

11 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Denmark | 13 | 21% |
| Sweden | 4 | 7% |
| Switzerland | 4 | 7% |
| France | 2 | 3% |
| Germany | 2 | 3% |

12 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Claus A. Andersson | General Partner | 5 | https://shizune.co/investors/profile/claus-andersson |
| Jacob Lange Moresco | Investment Director | 2 | https://shizune.co/investors/profile/jacob-lange-moresco |
| Line Jacobsen | Management Assistant | 0 | https://shizune.co/investors/profile/line-jacobsen |
| Peter Benson | Chairman and Managing Partner | 2 | https://shizune.co/investors/profile/peter-benson |
| Sten Verland | Co-Founder & General Partner | 2 | https://shizune.co/investors/profile/sten-verland |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| TargED Biopharmaceuticals | TargED Biopharmaceuticals is a biotechnology company that develops first-in-class biological drugs to improve treatment of thrombosis.TargED stands for Targeted Enzyme Delivery. Their biological drugs are unique by using small antibodies (“VhH”) to deliver enzymes to sites of thrombosis, enabling ‘targeted’ thrombolysis. | $25.3M | Series A | Dec 16, 2025 |  |
| Step Pharma | Step Pharma is a spin-off of Imagine Institute stemming from Pr. Alain Fischer’s research on genetic immunodeficiencies. Step Pharma is a joint venture between Imagine, a research and innovative healthcare institute, Sygnature Discovery, a leading provider of integrated drug discovery resource and expertise, and Kurma Partners, a major player inthe funding of healthcare and biotechnology in Europe. | $44.3M | Series C | Oct 15, 2025 |  |
| Resalis Therapeutics | Resalis Therapeutics sviluppa un farmaco in grado di inibire un micro-RNA per il trattamento di alcune malattie metaboliche | $10.9M | Series A | Jan 04, 2024 |  |
| Kynexis | Kynexis is advancing the first potential precision medicine for the treatment of cognitive impairment associated with schizophrenia (CIAS). | $61M | Series A | Nov 07, 2023 |  |
| Minervax | Minervax is pursuing the development of a vaccine against Group B streptococcus (GBS) infections by utilizing a particular fusion protein, which has proved to elicit good protective immunity. A vaccine including this fusion protein will likely elicit protective immunity against many clinically relevant GBS strains. | $57.4M |  | Oct 11, 2023 |  |
| DiogenX | DiogenX is a preclinical stage biotech company, specializing in the development of pancreatic beta-cell modulators for the treatment of Type 1 (T1D) and Type 2 Diabetes (T2D). The company, which also has research labs in Nice, France, aims to discover and develop a candidate molecule that regenerates pancreatic insulin-producing cells in patientswith diabetes, offering benefits in terms of quality of life and survival. It was discovered in the laboratory of Dr. Patrick Collombat (Inserm, CNRS, Nice University) in France, DiogenX is developing an innovative therapy with the potential to be the first beta-cell regeneration drug for diabetes. | $36.8M | Series A | May 10, 2023 |  |
| Teitur Trophics | Teitur Trophics is a biotech company developing circular peptides for neurodegenerative diseases. The company was founded in 2020 and is headquartered in Aarhus, Denmark. | $30M | Series A | Mar 14, 2023 |  |
| Rewind Therapeutics | Rewind Therapeutics is a developer of novel therapeutics intended to facilitate the treatment for neurological diseases.The company's first-in-class remyelinating therapeutics block inhibitory signals that prevent the expansion and migration of oligodendrocyte stem cells in order to promote effective remyelination, enabling medicalpractitioners to treat patients suffering from multiple sclerosis and other myelin-related diseases with efficacy. |  | Series B | Jan 25, 2023 |  |
| Rewind Therapeutics | Rewind Therapeutics is a developer of novel therapeutics intended to facilitate the treatment for neurological diseases.The company's first-in-class remyelinating therapeutics block inhibitory signals that prevent the expansion and migration of oligodendrocyte stem cells in order to promote effective remyelination, enabling medicalpractitioners to treat patients suffering from multiple sclerosis and other myelin-related diseases with efficacy. |  | Series A | Jan 25, 2023 |  |
| Minervax | Minervax is pursuing the development of a vaccine against Group B streptococcus (GBS) infections by utilizing a particular fusion protein, which has proved to elicit good protective immunity. A vaccine including this fusion protein will likely elicit protective immunity against many clinically relevant GBS strains. | $23.4M | Series C | Dec 15, 2022 |  |

10 of 61 investments shown.

## Co-investors
- [Novo Holdings](https://shizune.co/investors/profile/novo-a-s) — VC Fund, 13 deals together
- [Forbion Capital Partners](https://shizune.co/investors/profile/forbion-capital-partners) — VC Fund, 8 deals together
- [Kurma Partners](https://shizune.co/investors/profile/kurma-life-science-partners) — VC Fund, 8 deals together
- [Ysios Capital](https://shizune.co/investors/profile/ysios-capital) — VC Fund, 7 deals together
- [Industrifonden](https://shizune.co/investors/profile/industrifonden) — VC Fund, 6 deals together
- [M Ventures](https://shizune.co/investors/profile/merckventures) — VC Fund, 6 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [Vaekstfonden](https://shizune.co/investors/profile/v%C3%A6kstfonden) — VC Fund
- [PSV](https://shizune.co/investors/profile/preseed-innovation) — VC Fund
- [Seed Capital](https://shizune.co/investors/profile/seed-capital) — VC Fund

## Featured in investor lists
- [All Investors in Denmark](https://shizune.co/investors/investors-denmark)
- [All VC Funds in Denmark](https://shizune.co/investors/vc-funds-denmark)
- [Health Care Investors in Denmark](https://shizune.co/investors/health-care-investors-denmark)
- [Health Care VC Funds in Denmark](https://shizune.co/investors/health-care-vc-funds-denmark)
- [Biotechnology Investors in Denmark](https://shizune.co/investors/biotechnology-investors-denmark)
- [Biotechnology VC Funds in Denmark](https://shizune.co/investors/biotechnology-vc-funds-denmark)

## FAQ

### What does Sunstone Life Science Ventures invest in?

Sunstone Life Science Ventures invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Funding Round stage. Most of the 61 investments tracked by Shizune back companies in Denmark. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Sunstone Life Science Ventures's check size?

Sunstone Life Science Ventures typically joins rounds of $5.5M–$44M at Series A and $9.6M–$52M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Sunstone Life Science Ventures participates in.

### How do I contact Sunstone Life Science Ventures?

Public channels for Sunstone Life Science Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Sunstone Life Science Ventures?

The team at Sunstone Life Science Ventures includes Claus A. Andersson (General Partner), Jacob Lange Moresco (Investment Director) and Line Jacobsen (Management Assistant), among 8 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co